Cargando…

Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review

Advanced heart failure (HF) is a complex entity with a clinical course difficult to predict. However, most patients have a poor prognosis. This document addresses the modification of cardiovascular drugs in patients with advanced HF that are not candidates to heart transplantation or ventricular ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Sellés, Manuel, Grodzicki, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167993/
https://www.ncbi.nlm.nih.gov/pubmed/35677686
http://dx.doi.org/10.3389/fcvm.2022.883669
_version_ 1784720900965269504
author Martínez-Sellés, Manuel
Grodzicki, Tomasz
author_facet Martínez-Sellés, Manuel
Grodzicki, Tomasz
author_sort Martínez-Sellés, Manuel
collection PubMed
description Advanced heart failure (HF) is a complex entity with a clinical course difficult to predict. However, most patients have a poor prognosis. This document addresses the modification of cardiovascular drugs in patients with advanced HF that are not candidates to heart transplantation or ventricular assist device and are in need of palliative care. The adjustment of cardiovascular drugs is frequently needed in these patients. The shift in emphasis from life-prolonging to symptomatic treatments should be a progressive one. We establish a series of recommendations with the aim of adjusting drugs in these patients, in order to adapt treatment to the needs and wishes of each patient. This is frequently a difficult process for patients and professionals, as drug discontinuing needs to balance treatment benefit with the psychological adaption to having a terminal illness. We encourage the use of validated assessment tools to assess prognosis and to use this information to take clinical decisions regarding drug withdrawal and therapeutic changes. The golden rule is to stop drugs that are harmful or non-essential and to continue the ones that provide symptomatic improvement.
format Online
Article
Text
id pubmed-9167993
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91679932022-06-07 Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review Martínez-Sellés, Manuel Grodzicki, Tomasz Front Cardiovasc Med Cardiovascular Medicine Advanced heart failure (HF) is a complex entity with a clinical course difficult to predict. However, most patients have a poor prognosis. This document addresses the modification of cardiovascular drugs in patients with advanced HF that are not candidates to heart transplantation or ventricular assist device and are in need of palliative care. The adjustment of cardiovascular drugs is frequently needed in these patients. The shift in emphasis from life-prolonging to symptomatic treatments should be a progressive one. We establish a series of recommendations with the aim of adjusting drugs in these patients, in order to adapt treatment to the needs and wishes of each patient. This is frequently a difficult process for patients and professionals, as drug discontinuing needs to balance treatment benefit with the psychological adaption to having a terminal illness. We encourage the use of validated assessment tools to assess prognosis and to use this information to take clinical decisions regarding drug withdrawal and therapeutic changes. The golden rule is to stop drugs that are harmful or non-essential and to continue the ones that provide symptomatic improvement. Frontiers Media S.A. 2022-05-23 /pmc/articles/PMC9167993/ /pubmed/35677686 http://dx.doi.org/10.3389/fcvm.2022.883669 Text en Copyright © 2022 Martínez-Sellés and Grodzicki. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Martínez-Sellés, Manuel
Grodzicki, Tomasz
Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review
title Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review
title_full Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review
title_fullStr Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review
title_full_unstemmed Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review
title_short Modification of Cardiovascular Drugs in Advanced Heart Failure: A Narrative Review
title_sort modification of cardiovascular drugs in advanced heart failure: a narrative review
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167993/
https://www.ncbi.nlm.nih.gov/pubmed/35677686
http://dx.doi.org/10.3389/fcvm.2022.883669
work_keys_str_mv AT martinezsellesmanuel modificationofcardiovasculardrugsinadvancedheartfailureanarrativereview
AT grodzickitomasz modificationofcardiovasculardrugsinadvancedheartfailureanarrativereview